ContraFect Corp CFRXQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.02
- Day Range
- $0.02–0.02
- 52-Week Range
- $0.01–2.94
- Bid/Ask
- $0.01 / $0.10
- Market Cap
- $192,686.45
- Volume/Avg
- 16,239 / 24,124
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.contrafect.com
Valuation
Metric
|
CFRXQ
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CFRXQ
Financial Strength
Metric
|
CFRXQ
|
---|---|
Quick Ratio | 0.44 |
Current Ratio | 0.53 |
Interest Coverage | — |
Quick Ratio
CFRXQ
Profitability
Metric
|
CFRXQ
|
---|---|
Return on Assets (Normalized) | −169.35% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CFRXQ
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rjxrwwprv | Kvfmx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jvmqvqp | Ngzns | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gmvqscvjf | Czstdz | $97.8 Bil | |
MRNA
| Moderna Inc | Xtqmncfp | Gzp | $41.3 Bil | |
ARGX
| argenx SE ADR | Mbhznyzc | Gckk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jzfhpcpqb | Vbvb | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dbvjrxgb | Mpgxvs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xwrglll | Vbwsk | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sfnsmbjcx | Rfbrlv | $12.5 Bil | |
INCY
| Incyte Corp | Llpdzfkr | Yplmjvm | $11.6 Bil |